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Plasma protein biomarkers of Alzheimer’s disease
endophenotypes in asymptomatic older twins: early cognitive
decline and regional brain volumes
SJ Kiddle1,15, CJ Steves2,15, M Mehta3, A Simmons3,4, X Xu1,4, S Newhouse1,4, M Sattlecker1,4, NJ Ashton4,5, C Bazenet4,5,
R Killick5, J Adnan5, E Westman6, S Nelson7, H Soininen8,9, I Kloszewska10, P Mecocci11, M Tsolaki12, B Vellas13, C Curtis1,4,
G Breen1,4, SCR Williams3, S Lovestone14, TD Spector2,16 and RJB Dobson1,4,16
There is great interest in blood-based markers of Alzheimer’s disease (AD), especially in its pre-symptomatic stages. Therefore, we
aimed to identify plasma proteins whose levels associate with potential markers of pre-symptomatic AD. We also aimed to
characterise confounding by genetics and the effect of genetics on blood proteins in general. Panel-based proteomics was
performed using SOMAscan on plasma samples from TwinsUK subjects who are asymptomatic for AD, measuring the level of 1129
proteins. Protein levels were compared with 10-year change in CANTAB-paired associates learning (PAL; n= 195), and regional brain
volumes (n= 34). Replication of proteins associated with regional brain volumes was performed in 254 individuals from the
AddNeuroMed cohort. Across all the proteins measured, genetic factors were found to explain ~ 26% of the variability in blood
protein levels on average. The plasma level of the mitogen-activated protein kinase (MAPK) MAPKAPK5 protein was found to
positively associate with the 10-year change in CANTAB-PAL in both the individual and twin difference context. The plasma level of
protein MAP2K4 was found to suggestively associate negatively (Qo0.1) with the volume of the left entorhinal cortex. Future
studies will be needed to assess the speciﬁcity of MAPKAPK5 and MAP2K4 to eventual conversion to AD.
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INTRODUCTION
Currently, no treatments exist that delay or prevent onset of
Alzheimer’s disease (AD). Studies using magnetic resonance
imaging (MRI) and positron emission tomography brain scans
have revealed early signs of AD pathology in subjects up to ~ 4
and ~ 17 years before the onset of dementia, respectively.1
Pathological changes are likely to be least advanced in asympto-
matic subjects, and therefore potentially the most remediable in
this group. This is the motivation behind prevention trials in
asymptomatic subjects with MRI or positron emission tomography
evidence of early AD pathology.2
However, such brain scans can be relatively expensive and
require specialised facilities. Therefore, researchers are looking for
surrogate markers that are relatively inexpensive and non-
invasive, yet informative enough for enrichment of prevention
trials. Preliminary results reviewed in Lista et al.,3 Zürbig and Jahn4
and Chiam et al.5 suggest that blood may be a useful source of
such markers. Despite this, only two discovery studies have been
performed comparing blood proteins to AD-related phenotypes
exclusively in asymptomatic individuals.6,7
Recently, with the advent of panel-based proteomics, high-
throughput studies are becoming more feasible. One such
approach, SOMAscan (slow off-rate modiﬁed aptamer), allows
41000 proteins to be measured simultaneously and has already
been applied in AD research.8–11 This approach has not yet been
applied to discover blood markers of AD-related phenotypes in
asymptomatic individuals.
Although most blood protein biomarker studies have used
cohorts of individuals, one study of APOA1 blood DNA methylation
and protein level has been performed using 24 twin pairs
discordant for episodic memory performance. Two APOA1 CpG
sites were found to associate with discordant episodic memory.
However, the protein level of APOA1 was not found to differ
between discordant twins, possibly due to the small sample size
available.12
An advantage of studying ‘omics’ markers in twin cohorts is that
it allows genetic and environmental inﬂuences on markers and
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traits to be studied.13 If the monozygotic (MZ, that is, ‘identical’)
twin difference in the level of a marker associates with the twin
difference in trait value in twin pairs, this suggests that the
relationship between marker and trait is not confounded by age,
familial environment or genetics. Confounding of AD blood
biomarkers by age and/or genetics is a real possibility, as these
factors have been shown to affect both AD risk14,15 and plasma
protein levels.16–18 Despite this, twin differences have not yet
been exploited in studies of blood protein biomarkers of AD-
related phenotypes.
Genetic markers are generally more practical, robust and
inexpensive to measure in comparison with blood proteins. If
the association between a blood protein and an AD-related
phenotype is confounded by genetics, then it is likely that a
genetic test alone, rather than a protein test, would prove more
cost effective as a trial enrichment biomarker. One reason to
believe that genetic markers alone may not be optimal is that, it
has been shown that common variants, considered additively,
explain only 24–33% of the total AD variation.19,20
In terms of cognitive tests, the mini mental state examination
(MMSE) is known to not be very sensitive for detecting very early
AD-related changes in cognition. The paired associates learning
(PAL) task of the CANTAB cognition battery is thought to be more
sensitive at this stage. A 4-year study by de Jager et al.21 following
healthy older adults has shown that CANTAB-PAL, along with
another test called the Graded Naming Test, associates with
signiﬁcantly higher risk of conversion to mild cognitive impair-
ment or AD. However, the rate of CANTAB-PAL decline, which may
be more informative, has not yet been evaluated in this context. It
has also not yet been used as an endophenotype in a blood
biomarker study. In relation to age-related cognitive decline,
Steves et al.22 have shown that a larger proportion of variance in
10-year change in CANTAB-PAL total errors is explained by the
non-shared environment than by additive genetics. A plasma
protein biomarker measured in a single blood sample could be
more practical in some settings than cognitive testing over a 10-
year period in healthy older adults.
In this study, we use the TwinsUK and AddNeuroMed (ANM)
SOMAscan data sets. First a heritability analysis is performed and
then the association between plasma proteins and AD endophe-
notypes (10-year change in CANTAB-PAL and regional brain
volumes) is examined in asymptomatic individuals.
MATERIALS AND METHODS
Ethics statement
Informed consent was obtained for all subjects according to the
Declaration of Helsinki (1991), and protocols and procedures were
approved by the relevant local ethical committees at each site.
Discovery cohort—TwinsUK
Subjects used in this study were recruited from TwinsUK, a national
register of adult twins.23 Full details of subject selection is given in
Supplementary Methods. In brief, a total of 212 subjects (106 twin pairs)
were selected with longitudinal CANTAB-PAL data (~1999 and ~2009).22
These subjects had also been assessed using MMSE at the ~ 2009 visit.
Fasted EDTA plasma samples, taken a median of around 16 months before
CANTAB-PAL and MMSE testing (~2009), were used for proteomic analysis,
that is, around 8 years after the ~ 1999 assessment. Given the high level of
missingness in the APOE E4 genotype, and the small number of double-
APOE E4 carriers, we excluded double-APOE E4 carriers from further
analysis. Subjects who were homozygous for the APOE E4 allele (10
individuals), or whose plasma sample was haemolysed (six individuals,
determined by SomaLogic (Boulder, CO, USA)) or failed SOMAscan quality
control (1 individual) were excluded leaving 195 subjects (93 twin pairs
and 9 individuals).
Replication cohort—AddNeuroMed
Subjects used in the replication study were individuals from the ANM
cohort;24,25 full details are given in Supplementary Methods and are
summarised here. In total, 254 subjects with both plasma SOMAscan and
MRI baseline data, excluding subjects homozygous for the APOE E4 allele
(57 individuals), were available.9,10 Baseline EDTA plasma samples from
fasted subjects were used; see Supplementary Table 1 for a comparison of
the sample collection, processing and SOMAscan assay between TwinsUK
and ANM. Plasma samples were collected within a year and a half of MMSE
testing and MRI scanning. Quality control led to the exclusion of seven
subjects from ANM (Supplementary Methods). The remaining subjects
were diagnosed as either asymptomatic (control, N= 91), mild cognitive
impairment (N=81) or AD (N=82).
Proteomics
SOMAscan methods and data for TwinsUK and ANM have been described
previously,18 but are described again in Supplementary Methods, and are
brieﬂy summarised here. A single assay was used per plasma sample. All
proteomics data were transformed using the natural logarithm and
transformed to zero mean and unit s.d. In addition, protein values42.5 s.
d. from the mean were excluded as outliers.
Magnetic resonance imaging
Speciﬁcs of MRI pre-processing for each cohort are described below.
Owing to differences in methods, all MRI data were logged and
transformed to zero mean and unit s.d. to increase comparability.
TwinsUK. TwinsUK MRI scans were performed ~ 2 years after plasma
sampling (median 805 days, interquartile range (IQR) 151 days). Volumes of
the hippocampi and the combined Brodman’s areas 28 and 34 (equivalent
to the entorhinal cortex) in the TwinsUK cohort were obtained from 38
subjects using Diffeomorphic Anatomical Registration through Exponen-
tiated Lie Algebra,26 Statistical Parametric Mapping27 and MarsBar,28 as
fully described in Supplementary Methods.
AddNeuroMed. Volumes of the hippocampi and entorhinal cortices in the
ANM cohort were obtained using FreeSurfer 5.1.0 (freely available from
http://surfer.nmr.mgh.harvard.edu/) from 276 ANM subjects who had
undergone structural MRI. These regions were selected as they are known
to be related to early AD pathology, and were normalised by intracranial
volume.29 Detailed information about data acquisition, pre-processing and
quality control assessment have been described for this cohort in detail
elsewhere.29–33
APOE genotyping
Full details are given in Supplementary Methods, but in brief single-
nucleotide polymorphisms rs429358 and rs7412 were determined from
DNA samples using a TaqMan assay.
Statistical analysis
A detailed account of the statistical methodology is provided in
Supplementary Methods, and is summarised here. All statistical analyses
were performed in R 3.1.0, except for the transformation and 10-year
change calculations for cognitive scores that was performed in STATA 11.22
All double-APOE E4 carriers were excluded from analyses. Regressions in
the discovery cohort were performed using generalised estimation
equations to account for twin dependencies.34,35 Subject age, gender
and recruitment centre were used as co-variates in all relevant regressions.
The Benjamini–Hochberg (that is, false discovery rate) multiple testing
correction was used to generate Q-values with thresholds of Qo0.05 used
to indicate association and Qo0.1 to indicate suggestive association.
Analysis of association between a protein level and 10-year change in
CANTAB-PAL in the twin difference context was performed by calculating
twin differences in both, and performing a linear regression between the
two differences, covarying for twin-pair age. Twin modelling was
performed using structural equation modelling to estimate the proportion
of variance explained by additive genetics (A), shared environment (C) and
non-shared environment (E).36
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RESULTS
Characteristics of the TwinsUK-SOMAscan subcohort
Characteristics of the TwinsUK subjects with SOMAscan data are
summarised in Table 1. The MZ and dizygotic twins are matched
well, with the exception of APOE missingness. Despite not being
clinically diagnosed as cognitively impaired, there is variability in
the cognitive ability of these subjects (MMSE range 23–30). The
subject with MMSE score of 23 was included, as they showed no
functional deﬁcit and did not affect the results of the following
analyses (data not shown); in all other subjects the MMSE score
was 425.
Heritability of plasma protein levels in TwinsUK
Twin modelling was used to estimate the heritability of plasma
proteins measured by SOMAscan (Supplementary Table 2). The
median proportion of variance of plasma protein levels explained
by additive genetics (A) was found to be 26% (IQR 3–46%). The
proportion explained by total familial factors (additive genetics (A)
or twin-shared environment (C)) was 34% (IQR 3–74%). Finally, a
median of 54% (IQR 40–75%) of the variance in plasma protein
levels was found to be explained by non-shared environmental
factors (E), including technical variability. The results were
comparable when a Van der Waerden transformation was used
to overcome deviations from the normal distribution
(Supplementary Table 2).
Plasma protein markers of cognitive scores in asymptomatic
individuals from TwinsUK
Levels of plasma proteins in TwinsUK subjects were ﬁrst compared
with MMSE scores, both as a continuous and dichotomised
variable. No protein was found to be associated in either analysis
(Supplementary Tables 4–5).
No protein passed multiple testing corrections for association
with CANTAB-PAL total errors in 1999 or 2009; however,
MAPKAPK5 was found to be associated with the 10-year change
in CANTAB-PAL total errors (Figure 1a; β= 0.48, Q= 0.0059;
Supplementary Tables 5–7).
In total, 54 MZ twin pairs had complete data on plasma
MAPKAPK5 levels and 10-year change in CANTAB-PAL total errors.
Within these subjects, MAPKAPK5 was found to associate with 10-
year change in CANTAB-PAL total errors in the context of MZ-pair
differences (Figure 1b; β= 0.55, P= 0.030). In a twin model, non-
shared environmental factors (E) were found to explain 90% (95%
conﬁdence interval (CI): 64–100%) of the variance in the plasma
level of MAPKAPK5 when a Van der Waerden transformation was
applied (A = 10% (CI: 0–36%), C = 0% (CI: 0–23%) and E= 90% (CI:
64–100%); Supplementary Table 1).
Plasma protein markers of MRI measures in asymptomatic
individuals from TwinsUK
Plasma protein levels were then compared with selected regional
brain volumes derived from structural MRI scans, taking into
Table 1. Characteristics of the discovery cohort (TwinsUK) with SOMAscan data.
Monozygotic subjects Dizygotic subjects Subjects without twin-pair data
Number of subjects 110 (55 pairs) 76 (38 pairs) 9
Number of MRI scan subjects 34 0 2
Age (median (IQR)) 65 (62–71) 63 (59–68) 67 (63–74)
% Female 100 100 100
APOE E4 (# alleles 0/1 {NA}) 44/18 {48} 61/9 {6} 8/0 {1}
MMSE (median (IQR) {# NA}) 29 (29–30) {7} 29 (29–30) {2} 28 (27–30)
Abbreviations: IQR, interquartile range; MMSE, mini mental state examination; MRI, magnetic resonance imaging; NA, individuals with missing data for this
measure. Double-APOE E4 carriers were excluded from this study.
Figure 1. The relationship between plasma MAPKAPK5 levels and
10-year change in CANTAB-PAL in TwinsUK. Scatterplot comparing
(a) plasma MAPKAPK5 levels and 10-year change in CANTAB-PAL in
TwinsUK, or (b) MZ twin differences in both. Points are coloured by
APOE E4 data. (a) GEEs covarying for age and taking into account
twin relatedness show an association between plasma MAPKAPK5
and the 10-year change in CANTAB-PAL (β= 0.48, Q= 0.0059). (b)
Linear regression covarying for age shows an association between
plasma MAPKAPK5 and the 10-year change in CANTAB-PAL in the
MZ twin difference context (β= 0.55, P= 0.030). CANTAB-PAL,
CANTAB-paired associates learning; GEE, generalised estimation
equation; MZ, monozygotic; RFU, relative ﬂuorescence unit.
Plasma markers of Alzheimer’s phenotypes in twins
SJ Kiddle et al
3
Translational Psychiatry (2015), 1 – 6
account age and twin relatedness (Supplementary Tables 8–11).
These selected regions of interest—the left and right hippocam-
pus and entorhinal cortices (LE and RE, respectively)—are known
to show early pathology and greater atrophy in AD.1,37
Full results are given in Supplementary Tables 8–11. The plasma
level of one protein—FAM107B—was found to associate with the
volume of both the LE (β= 1.05, Q= 0.034) and RE (β= 0.77,
Q= 0.015) cortices. Two proteins associated with the volume of
one region (Qo0.05) were also associated with the volume of
three out of four regions at a suggestive threshold of Qo0.1,
NSF1C (positively with left hippocampus, LE and RE) and MAP2K4
(negatively with right hippocampus, LE and RE; Supplementary
Tables 8–11). The association between MAP2K4 and LE cortex
volume in TwinsUK is shown in Figure 2a.
Of the three proteins most consistently associated with multiple
brain regions—FAM107B, NSF1C and MAP2K4—only MAP2K4 was
also found to be nominally associated with the 10-year change in
CANTAB-PAL total errors, (rank = 16th, β=− 0.24, P-value = 0.026,
Q=~ 1.0; Supplementary Table 7). Similarly, MAPKAPK5 was
nominally associated with the volume of the right hippocampus
(rank = 93rd, β=− 0.28, P-value = 0.039, Q= 0.48; Supplementary
Table 6).
Replication of discovery results in ANM
We wished to replicate the association of plasma levels of the
proteins FAM107B, NSF1C and MP2K4 with MRI regional volumes
in the ANM SOMAscan data. However, as TwinsUK consists of
asymptomatic females, whereas ANM also includes males and
cognitively impaired individuals, we wished to see whether this
had any impact on replication. We therefore performed the
replication analysis in ANM in all subjects, in just the asympto-
matic (control) subjects and in just the asymptomatic females
separately. The characteristics of the relevant ANM subcohorts are
given in Table 2.
The plasma level of the protein MAP2K4 in asymptomatic
female ANM subjects was found to suggestively associate with the
volume of LE (β=− 0.64, P= 0.0025, Q= 0.088), in a direction
consistent with the discovery cohort (Figure 1). Although this
trend is visible in Figure 2b, there is a possible outlier remaining in
the data set (with the lowest volume and highest protein level).
Removing this possible outlier reduces the signiﬁcance but does
not remove the association of MAP2K4 with the volume of LE in
asymptomatic females (β=− 0.54, P= 0.014).
No other combination of proteins, subjects or regions showed
an association (Supplementary Table 12). However, the directions
of association were consistent for all the proteins between
asymptomatic females from ANM and TwinsUK, and the models
including these proteins appeared to explain a higher proportion
of the variance (R2) in asymptomatic females versus the other
subject groups.
Twin models suggest that plasma levels of MAP2K4 may be
more affected by additive genetics than by environmental
inﬂuences (A = 72% (CI: 15–83%), C = 0% (CI: 0–55%) and E= 28%
(CI: 17–39%); Supplementary Table 1).
DISCUSSION
In this study we have applied the following methodologies to the
study of blood protein biomarkers of AD endophenotypes for the
ﬁrst time: (1) the use of panel-based proteomics in an asympto-
matic cohort, (2) the use of CANTAB-PAL as an endophenotype
and (3) the use of twin samples. We also believe this is the third
discovery study of blood protein markers of AD endophenotypes
in asymptomatic individuals, and the largest twin high-throughput
proteomics study performed to date.
We are only aware of one other study estimating the heritability
of blood protein levels in a high-throughput manner.17 The
estimates from our study suggest a heritability that is at least
twice as high on average, further demonstrating the potential for
genetic confounding of blood protein biomarkers.
The suggestive/nominal replication of MAP2K4 in ANM, again in
asymptomatic individuals, is consistent with the hypothesis that it
shows the greatest variability in the asymptomatic phase of AD,
which is what is required of an early biomarker. This may be why it
has not been reported in previous AD blood biomarker studies,
which have mostly focused on later disease stages. As well as
being negatively associated with entorhinal cortex volume,
Figure 2. The association between plasma MAP2K4 levels and (a) left
parahippocampal volume in TwinsUK or (b) left entorhinal cortex
volume in ANM. Scatterplot comparing plasma MAP2K4 levels with
the volume of the left entorhinal cortex are given for the two
cohorts. Points are coloured by APOE E4 data and whether they
appear to be outliers. (a) GEEs covarying for age and taking into
account twin relatedness show a suggestive association (Qo0.1)
between plasma MAP2K4 and the volume of the left entorhinal
cortex in TwinsUK. (b) Linear regression covarying for age and
centre shows a suggestive association (Qo0.1) between plasma
MAP2K4 and the volume of the left entorhinal cortex in ANM, when
a possible outlier (in blue) is included (β=− 0.64, P= 0.0025 and
Q= 0.088), or nominal association (Po0.05) when it is excluded
(β=− 0.54 and P= 0.014). ANM, AddNeuroMed; GEE, generalised
estimation equation.
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MAP2K4 has been linked to phosphorylation of tau38 and of
amyloid precursor protein through c-Jun N-terminal kinase.39 In
both cases, these phosphorylation events are believed to lead to
increased AD pathology.
MAPKAPK5 has mostly been studied in the context of cancer40
and rheumatoid arthritis,41 and, to the best of our knowledge, has
not previously been implicated in AD. However, it is interesting
that we ﬁnd two different mitogen-activated protein kinases
(MAPKs) whose levels in plasma associate with AD
endophenotypes.
The use of longitudinal change in CANTAB-PAL, a cognitive test
that is sensitive to early cognitive decline, was critical in the
discovery of MAPKAPK5 as a potential biomarker relevant to AD.
This demonstrates the importance of studying decline in cognitive
abilities using sensitive tests in asymptomatic older adults.
By showing an association between MAPKAPK5 and 10-year
change in CANTAB-PAL total errors in the MZ twin difference
context, we have demonstrated that the association of MAPKAPK5
and change in cognitive ability in older adults is independent of
genetic and twin-shared environmental factors. This is consistent
with twin modelling, which suggests that plasma MAPKAPK5
levels are mostly affected by non-shared environmental factors.
This has also been demonstrated for 10-year change in CANTAB-
PAL total errors in a previous study.22 Genetic risk, and many
aspects of twin-shared environment (such as maternal and family
factors) have been implicated in cognitive ageing and dementia,
but are currently not modiﬁable. Given our ﬁndings, we
hypothesise that MAPKAPK5 may be a biomarker of modiﬁable
cognitive ageing. Selection of individuals for intervention studies
whose risk is modiﬁable may lead to improved outcomes.
The failed replication of ﬁndings for proteins FAM107B and
NSFL1C may indicate that the original ﬁndings are false positives,
or they may indicate failed replication due to the technical
differences or small sample sizes present in this study. However, in
asymptomatic females of the replication cohort, the directions of
association of all of the proteins were consistent with discovery
ﬁndings. In addition, the proportion of variance explained by the
models was largest in the asymptomatic females. This is consistent
with a failure of replication due to small sample size and therefore
insufﬁcient statistical power. This suggests that the sample size of
this replication cohort may have been a limitation.
There is great demand for inexpensive and relatively non-
invasive markers that could be used to identify asymptomatic
subjects at risk of AD to recruit into prevention trials. In this study,
we started by demonstrating heritability of plasma protein levels,
which raise the potential of genetic confounding of plasma
protein biomarkers of disease. We then looked for plasma protein
biomarkers of AD endophenotypes in asymptomatic twins. The
plasma protein level of two MAPKs—MAP2K4 and MAPKAPK5—
were identiﬁed as possible biomarkers of early AD. MAPKAPK5 was
shown to be associated with decline in cognitive ability in the
context of MZ twin differences. This suggests that it conveys
information on cognitive ability that is complementary to genetic
markers, and may be a biomarker of modiﬁable cognitive ageing.
Future studies will need to assess the speciﬁcity of MAPKAPK5 and
MAP2K4 to eventual AD, and their potential utility as enrichment
biomarkers for clinical trials.
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